Argatroban has been assigned to pregnancy category B by the FDA. Animal studies have failed to reveal evidence of fetal harm. There are no controlled data in human pregnancy. Argatroban should only be given during pregnancy when need has been clearly established.

See references

There are no data on the excretion of argatroban into human milk. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Argatroban has been detected in breast milk in animal studies.

See references